Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KB 707

Next Previous
Drug Profile

KB 707

Alternative Names: KB-707

Latest Information Update: 02 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Krystal Biotech
  • Class Antineoplastics; Gene therapies; Immunotherapies
  • Mechanism of Action Gene transference; Immunologic cytotoxicity; Interleukin 12 replacements; Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Lung cancer; Solid tumours

Most Recent Events

  • 02 Sep 2025 Phase-I/II clinical trials in Lung cancer (Late-stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (Inhalation) (NCT06228326)
  • 21 Aug 2025 Krystal Biotech expects End of Phase II meeting with the US FDA to discuss potential development pathways to support the registration of inhaled KB707 in October 2025
  • 21 Aug 2025 Updated efficacy data from phase I/II KYANITE-1 trials in lung cancer released by Krystal Biotech

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top